FILING ANALYSIS · WEDNESDAY, NOVEMBER 18

Lantern Pharma Inc. LTRN — 8-K: Results of Operations and Financial Condition

negative

Dilution from the $4.0 million registered direct offering and concurrent private placement, as well as the leadership transition with CFO David Margrave appointed as Interim CEO, may weigh on the stock, despite some positive updates on the company's pipeline, including the engagement of the first clinical site for the Phase 1b/2 trial in triple negative breast cancer and the approval of the amende

The filing

8-K - Lantern Pharma Inc. (0001763950) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+